Arrowhead Pharmaceuticals Inc. (ARWR) Misses Q1 EPS by 100c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 inches lower as Middle East tensions outweigh tech gains
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Chardan Capital Markets Reiterates Buy Rating on Arrowhead Pharma (ARWR)
February 11, 2025 7:46 AM ESTChardan Capital Markets analyst Keay Nakae reiterated a Buy rating and $60.00 price target on Arrowhead Pharma (NASDAQ: ARWR)
The analyst comments "The company is currently evaluating plozasiran in three other phase III studies: SHASTA-3 and SHASTA-4 in adults with SHTG (currently enrolling), and MUIR-3 in adults... More
